title: [Clinical observation of lower extremity deep venous hrombosis (DVT) postoperative fracture treated by Maixuekang capsule and low molecular heparin calcium (Subilin)].
abstract: OBJECTIVE
  To observe the clinical curative effects of lower extremity deep venous thrombosis (DVT) postoperative fracture treated by maixuekang capsule and low molecular heparin calcium (Subilin).
  
  
  METHODS
  From Feb 2008 to Apr 2010, 214 cases of lower extremity DVT postoperative fracture were randomly divided into experimental group and control group. The 107 cases of them were treated by maixuekang capsule based on the comprehensive treatment.
  
  
  RESULTS
  The 89 cases were cured and improved in the observation group, but 18 cases were ineffectiveness. The 66 cases were cured and improved in the control group, but 41 cases were ineffectiveness. Maixuekang capsule group had 83. 18% (89/107) total effective rate and 61.68% (66/107) total effective rate in the control group. There was significant difference between the two groups (P < 0.05). After the treatment, the perimeter between the suffered limb and the healthy one was significantly reduced, the blood rheology examination had been improved significantly. There was also significant difference between the two groups (P < 0.05).
  
  
  CONCLUSIONS
  Maixuekang capsule for lower extremity deep vein thrombasis has good effect It has both thrombolytic and anticoagulant effects for lower extremity DVT postoperative fracture treated by maixuekang capsule and low molecular heparin calcium (Subilin). It's a recommended treatment.
authors.affiliation: Zhengzhou Orthopaedics Hospital, Zhengzhou 450052, China.
authors.forename: Qingfeng
authors.initials: Q
authors.lastname: Liu
authors.forename: Yijie
authors.initials: Y
authors.lastname: Chang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002214:Capsules; D005260:Female; D050723:Fractures, Bone / Q000601:surgery*; D006439:Hemodynamics / Q000187:drug effects; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D035002:Lower Extremity / Q000293:injuries* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D055815:Young Adult
chemical_list: D002214:Capsules; D006495:Heparin, Low-Molecular-Weight